Muscle Strength and Exercise Capacity in Sarcoidosis Patients
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||Exercise Capacity, Muscle Strength and Fatigue in Sarcoidosis: a Two-year Follow-up Study|
- Exercise capacity, muscle strength and fatigue in sarcoidosis: a two-year follow-up study [ Time Frame: 30 months ] [ Designated as safety issue: No ]6MWD and muscle strength measurements of arm (isometric strength of the elbow flexors) and leg (isokinetic peak torques of the hamstrings and quadriceps) muscles. Questionnaires: WHOQOL-bref and Fatigue Assessment Scale (FAS).
|Study Start Date:||January 2009|
|Study Completion Date:||September 2011|
|Primary Completion Date:||August 2009 (Final data collection date for primary outcome measure)|
Sarcoidosis patients referred to the ild care team of the outpatient clinic of the department of Respiratory Medicine of the MUMC and also participated in the baseline study between November 2008 and September 2009 will be included in this study
The aim of this study is to examine exercise capacity, muscle strength and fatigue in sarcoidosis. In this longitudinal study the changes in prevalence of exercise intolerance, reduced muscle strength and fatigue will be established in a two-year follow-up. Also the relation between these physical impairments in time and other clinical parameters, such as QOL, will be established.
Study design: sarcoidosis patients referred to the ild care team of outpatient clinic of the department of Respiratory Medicine of the MUMC and also participated in the baseline study between November 2008 and September 2009 will be included in this longitudinal study. A six-minute walk test and peripheral muscle strength measurements (included in the regular clinical work-up of sarcoidosis patients) will be performed under supervision of a physical therapist at the department of physical therapy of the MUMC. Moreover, the patients will be asked to complete the WHOQOL-bref questionnaire and the Fatigue Assessment Scale. A maximum of 124 patients will be included.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00854672
|Maastricht University Medical Center|
|Principal Investigator:||Rik Marcellis, MSc||Maastricht University Medical Center|
|Study Chair:||Marjolein Drent, MD, PhD||Maastricht University Medical Center and University Maastricht|
|Study Director:||Ton Lenssen, MSc, PhD||Maastricht UMC and University of Maastricht|